INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
04/20/2026
Back to search
Official data from USPTO
DBV TECHNOLOGIES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
04/21/2026
Trademark type
Combined
Nice classes
5, 10, 42, 44
Filing date
11/06/2018
Registration date
07/23/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/20/2025
Last transaction
04/21/2026
Responsible office
United States Patent and Trademark Office
Status code
707
Official register
Principal Register
Drawing code
3
Owner type
98
Owner location
Châtillon, FR
Examiner
RIEPEL, CHRISTINA MAXINE
Current location
Historical data usage
Mark description
The mark consists of the wording a "DBV TECHNOLOGIES" in black and a design comprised of two gray concentric circles above a cyan curved line. White is not claimed as a feature of the mark and represents background or transparent areas, only.
Holders and representatives
Holders
D. T. (pessoa física)
D. T. (pessoa física)
Representatives
Anthony E. Bennett Hoffmann & Baron, LLP
Technical classification
Nice Classes
Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
adhesive patches enabling cutaneous or epicutaneous administration of powdered medicated or pharmaceutical substances for humans or animals featuring pharmaceutical preparations for treatment of allergiesinflammatory and autoimmune diseases; drug delivery patch containing a preparation in powder form for medical use for the treatment of allergiesinflammatory and autoimmune diseases; medicated occlusive patch enabling the cutaneous absorption of a powdered medicated substance featuring pharmaceutical preparations for treatment of allergiesinflammatory and autoimmune diseases
Class 10
medical apparatusinstruments and devices for the cutaneous or epicutaneous administration of powdered medicated or cosmetic substances for humans or animalsdrug delivery patches sold without medication; occlusive dispenser for medical use sold without medication; medical instrument using electrostatic properties from a biocompatible supportnamely epicutaneous patches sold without medication
Class 42
research in the field of immunotherapy; design of a scientific method for epicutaneous desensitization via immunotherapy without prior preparation of the skin other than simple and light cleaning in order to leave the cell structure of the skin intact; scientific research in the field of processing and treatment of allergies; scientific research in the field of allergy treatment for a treatment to be applied repeatedly to the skin of the patient without prior preparation of the skinother than simple and light cleaning in order to leave the cell structure of the skin intactthus avoiding the transfer of the allergen into the blood; drug discovery being scientific research and development of allergens; design of methods for the treatment of allergy-causing by the combination of immune cells from the skin; design of methods for treating allergies via the application of a patch to the unbroken skin of the patient without prior preparation of the skin other than simple and light cleaning in order to leave the cell structure of the skin intact
Class 44
medical services applying a method for desensitizing by immunotherapy; medical treatment of allergiesinflammatory and autoimmune diseases via allergen administration by placing a patch on the patient's intact skin while preventing the allergen from getting into the blood; medical treatment of allergiesinflammatory and autoimmune diseases using a method for desensitizing by epicutaneous immunotherapy; medical treatment of allergiesinflammatory and autoimmune diseases by epicutaneous immunotherapy without prior preparation of the skin other than simple and light cleaning in order to leave the cell structure of the skin intact; medical consultancy in the field of desensitization to combat allergies
Publications
History of USPTO decisions and trademark events.
39 publications found
NA15
SEC. 15 ACKNOWLEDGEMENT - E-MAILED
08/20/2025
15AK
REGISTERED - SEC. 15 ACKNOWLEDGED
08/20/2025
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
08/20/2025
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
08/20/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/11/2025
ES71
TEAS SECTION 71 RECEIVED
07/22/2025
E15R
TEAS SECTION 15 RECEIVED
07/22/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/16/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
09/16/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/16/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/16/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/16/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/16/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/23/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
07/13/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/15/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/01/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/06/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/15/2019
FIMP
FINAL DISPOSITION PROCESSED
11/15/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/23/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
07/23/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/07/2019
PUBO
PUBLISHED FOR OPPOSITION
05/07/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/17/2019
RFNT
REFUSAL PROCESSED BY IB
03/16/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/15/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/14/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/14/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/14/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/28/2019
RFRR
REFUSAL PROCESSED BY MPU
02/28/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/20/2019
CNRT
NON-FINAL ACTION WRITTEN
02/19/2019
MAFR
APPLICATION FILING RECEIPT MAILED
02/15/2019
DOCK
ASSIGNED TO EXAMINER
02/11/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/11/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/07/2019
Continuous trademark protection
Get notified about every new filing that threatens DBV TECHNOLOGIES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.